Regeneron Releases New Linvoseltamab Analysis As It Inches Toward ASH, Regulatory Filing

The BCMAxCD3-directed bispecific for multiple myeloma is one of the crown jewels of Regeneron’s larger program to develop bispecifics as it diversifies beyond its traditional core franchises.

Regeneron announced an analysis from the Phase I/II LINKER-MM1 trial of linvoseltamab • Source: Shutterstock

On the eve of the American Society of Hematology annual meeting, Regeneron Pharmaceuticals, Inc. released data on its multiple myeloma drug candidate linvoseltamab that should support its submission to the US Food and Drug Administration this year. Linvoseltamab isn’t getting top billing among Regeneron’s presentations at ASH, but the Tarrytown, NY-based company will present additional data that will support the drug’s profile in a competitive class.

Regeneron released 7 December an analysis of the pivotal Phase I/II LINKER-MM1 trial that showed a 71% objective response rate...